Metagenomi, Inc. Insider Trading

MGX

⊜ Compare

Last 12 months

Insiders bought 23K and sold 33K on the open market.

None of the selling was scheduled in advance under a 10b5-1 plan.

Net open-market

−10K

1 buy · 13 sales

Under a 10b5-1 plan

of the value sold

Insiders who bought / sold

1 / 4

executives and directors

Last open-market buy

Sep 2026

Sep 9, 2026

Get an email when MGX's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 9	Laurence Reid Director	Bought 2 parts	20,000	$1.17 average	23K	New	Form 4
Sep 8	Matthew Wein See Remarks	SoldNo plan	358	$1.16	$415	0.3%	Form 4
Sep 8	Jian Irish See Remarks	SoldNo plan	2,140	$1.16	2K	0.3%	Form 4
Sep 8	Pamela Wapnick Chief Financial Officer	SoldNo plan	1,911	$1.16	2K	0.9%	Form 4
Jun 5	Pamela Wapnick Chief Financial Officer	SoldNo plan	2,884	$1.30	4K	1.4%	Form 4
Jun 5	Jian Irish See Remarks	SoldNo plan	3,737	$1.30	5K	0.6%	Form 4
Jun 5	Matthew Wein See Remarks	SoldNo plan	558	$1.30	$725	0.4%	Form 4
Mar 5	Pamela Wapnick Chief Financial Officer	SoldNo plan	1,581	$1.60	3K	0.8%	Form 4
Mar 5	Matthew Wein See Remarks	SoldNo plan	482	$1.60	$771	0.4%	Form 4
Mar 5	Jian Irish Chief Executive Officer	SoldNo plan	1,607	$1.60	3K	0.3%	Form 4
Dec 5, 2025	Brian C. Thomas Director	SoldNo plan	3,830	$1.77	7K	0.2%	Form 4
Dec 5, 2025	Matthew Wein See Remarks	SoldNo plan	199	$1.77	$352	0.2%	Form 4
Dec 5, 2025	Pamela Wapnick Chief Financial Officer	SoldNo plan	1,576	$1.77	3K	0.8%	Form 4
Dec 5, 2025	Jian Irish Chief Executive Officer	SoldNo plan	1,602	$1.77	3K	0.3%	Form 4
Sep 5, 2025	Brian C. Thomas Director	SoldNo plan	2,701	$1.81	5K	0.1%	Form 4
Sep 5, 2025	Pamela Wapnick Chief Financial Officer	SoldNo plan	1,576	$1.81	3K	0.8%	Form 4
Sep 5, 2025	Jian Irish Chief Executive Officer	SoldNo plan	1,602	$1.81	3K	0.3%	Form 4
Sep 5, 2025	Matthew Wein See Remarks	SoldNo plan	199	$1.81	$360	0.2%	Form 4
Jun 6, 2025	Matthew Wein See Remarks	SoldNo plan	199	$1.75	$348	1.2%	Form 4
Jun 6, 2025	Sarah B. Noonberg Chief Medical Officer	SoldNo plan	5,239	$1.75	9K	4.6%	Form 4
Jun 6, 2025	Pamela Wapnick Chief Financial Officer	SoldNo plan	1,576	$1.75	3K	2.1%	Form 4
Jun 6, 2025	Brian C. Thomas Chief Executive Officer	SoldNo plan	10,785	$1.75	19K	0.4%	Form 4
Jun 6, 2025	Jian Irish See Remarks	SoldNo plan	6,390	$1.75	11K	2.0%	Form 4
Mar 5, 2025	Matthew Wein See Remarks	SoldNo plan	930	$1.87	2K	8.9%	Form 4
Mar 5, 2025	Pamela Wapnick Chief Financial Officer	SoldNo plan	1,808	$1.87	3K	2.9%	Form 4
Dec 5, 2024	Pamela Wapnick Chief Financial Officer	SoldNo plan	1,559	$1.86	3K	2.5%	Form 4

Sep 9
Laurence Reid
Director · bought 20,000 at avg $1.17
23K
New position
Sep 8No plan
Matthew Wein
See Remarks · sold 358 at $1.16
$415
0.3% of stake
Sep 8No plan
Jian Irish
See Remarks · sold 2,140 at $1.16
2K
0.3% of stake
Sep 8No plan
Pamela Wapnick
Chief Financial Officer · sold 1,911 at $1.16
2K
0.9% of stake
Jun 5No plan
Pamela Wapnick
Chief Financial Officer · sold 2,884 at $1.30
4K
1.4% of stake
Jun 5No plan
Jian Irish
See Remarks · sold 3,737 at $1.30
5K
0.6% of stake
Jun 5No plan
Matthew Wein
See Remarks · sold 558 at $1.30
$725
0.4% of stake
Mar 5No plan
Pamela Wapnick
Chief Financial Officer · sold 1,581 at $1.60
3K
0.8% of stake
Mar 5No plan
Matthew Wein
See Remarks · sold 482 at $1.60
$771
0.4% of stake
Mar 5No plan
Jian Irish
Chief Executive Officer · sold 1,607 at $1.60
3K
0.3% of stake
Dec 5, 2025No plan
Brian C. Thomas
Director · sold 3,830 at $1.77
7K
0.2% of stake
Dec 5, 2025No plan
Matthew Wein
See Remarks · sold 199 at $1.77
$352
0.2% of stake
Dec 5, 2025No plan
Pamela Wapnick
Chief Financial Officer · sold 1,576 at $1.77
3K
0.8% of stake
Dec 5, 2025No plan
Jian Irish
Chief Executive Officer · sold 1,602 at $1.77
3K
0.3% of stake
Sep 5, 2025No plan
Brian C. Thomas
Director · sold 2,701 at $1.81
5K
0.1% of stake
Sep 5, 2025No plan
Pamela Wapnick
Chief Financial Officer · sold 1,576 at $1.81
3K
0.8% of stake
Sep 5, 2025No plan
Jian Irish
Chief Executive Officer · sold 1,602 at $1.81
3K
0.3% of stake
Sep 5, 2025No plan
Matthew Wein
See Remarks · sold 199 at $1.81
$360
0.2% of stake
Jun 6, 2025No plan
Matthew Wein
See Remarks · sold 199 at $1.75
$348
1.2% of stake
Jun 6, 2025No plan
Sarah B. Noonberg
Chief Medical Officer · sold 5,239 at $1.75
9K
4.6% of stake
Jun 6, 2025No plan
Pamela Wapnick
Chief Financial Officer · sold 1,576 at $1.75
3K
2.1% of stake
Jun 6, 2025No plan
Brian C. Thomas
Chief Executive Officer · sold 10,785 at $1.75
19K
0.4% of stake
Jun 6, 2025No plan
Jian Irish
See Remarks · sold 6,390 at $1.75
11K
2.0% of stake
Mar 5, 2025No plan
Matthew Wein
See Remarks · sold 930 at $1.87
2K
8.9% of stake
Mar 5, 2025No plan
Pamela Wapnick
Chief Financial Officer · sold 1,808 at $1.87
3K
2.9% of stake
Dec 5, 2024No plan
Pamela Wapnick
Chief Financial Officer · sold 1,559 at $1.86
3K
2.5% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch MGX, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Biological Products, (No Diagnostic Substances) · Pick stocks to compare with MGX

CompareIntrinsic value

ATRAAtara Biotherapeutics, Inc.

$8.37+2.07%15

ACLXArcellx, Inc.

No recent price10

GLUEMonte Rosa Therapeutics, Inc.

$10.82+3.94%10

LENZLENZ Therapeutics, Inc.

$3.46-1.14%10

SCLXScilex Holding Company

$1.83-1.08%0

PTHSPelthos Therapeutics Inc.

$10.15-5.84%0

SGMOSangamo Therapeutics Inc.

$0.12-0.20%10

CCCCC4 Therapeutics Inc.

$3.12-2.80%33

Spot a number that looks wrong? Check it in MGX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing MGX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.